Paul Tudor Jones’s MoonLake Immunotherapeutics MLTX Stock Holding History

Paul Tudor Jones’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	58,740 -2,837	-5%	-$51.4K	﹤0.01%	2322
2026 Q1	$1.15M	Sell	61,577 -41,939	-41%	-$695K	﹤0.01%	2265
2025 Q4	$1.36M	Buy	+103,516	New	+$1.22M	﹤0.01%	2073
2025 Q3	–	Sell	-31,714	Closed	-$1.65M	–	3683
2025 Q2	$1.5M	Buy	31,714 +122	+0.4%	+$4.97K	﹤0.01%	1865
2025 Q1	$1.23M	Buy	+31,592	New	+$1.36M	﹤0.01%	1678
2024 Q4	–	Sell	-31,840	Closed	-$1.61M	–	3337
2024 Q3	$1.61M	Buy	31,840 +4,667	+17%	+$219K	0.01%	1331
2024 Q2	$1.19M	Sell	27,173 -4,238	-13%	-$180K	0.01%	1363
2024 Q1	$1.58M	Buy	31,411 +1,257	+4%	+$68.2K	0.01%	1136
2023 Q4	$1.82M	Buy	30,154 +13,059	+76%	+$673K	0.01%	1143
2023 Q3	$974K	Buy	17,095 +3,546	+26%	+$196K	0.01%	1313
2023 Q2	$691K	Buy	+13,549	New	+$365K	0.01%	1528

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's MLTX Position: Q2 2026 in Review

Paul Tudor Jones reduced its MoonLake Immunotherapeutics (MLTX) stake by 4.6% in Q2 2026, selling an estimated $51.4K and leaving 58,740 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Paul Tudor Jones first reported a position in MLTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $1.82M in Q4 2023. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Paul Tudor Jones held 58,740 shares of MoonLake Immunotherapeutics worth $1.14M as of Q2 2026.
Paul Tudor Jones sold 2,837 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $51.4K.
MoonLake Immunotherapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2322 holding.
Paul Tudor Jones first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 11 quarters since.
Paul Tudor Jones's MoonLake Immunotherapeutics position peaked at $1.82M in Q4 2023.
171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.